FDA Approved Abbreviated New Drug Application of Mayne Pharma Inc.’s Mitoxantrone Injection (Multiple Doses)
The USFDA recently granted the final approval for Mayne Pharma (USA) Inc.’s Abbreviated New Drug Application for Mitoxantrone Injection, USP packaged in 20mg, 25mg and 30mg multiple-dose presentations.
Mitoxantrone is the generic version of Serono's Novantrone®, the only USFDA-approved treatment for worsening Multiple Sclerosis (MS).
Mayne Pharma Inc.’s division specializes in generic injectable pharmaceuticals in a number of defined therapeutic areas: oncology and anesthesia/pain management, treatment drugs for cardiac conditions and hypertension.
Source: PR Newswire
.jpg)
Comment Preview